(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
‘Serving is not just a place’: Bayside Church Granite Bay reimagines annual mission amid conflict in Mexico - 2Wonderful Sea shores All over the Planet
- 3Artemis 2 astronauts fly around the moon in record-breaking lunar loop by NASA
- 4New images reveal interstellar comet 3I/ATLAS approaching Earth
- 5The Most Important Crossroads in Olympic History
- Some Americans say they'll go without health insurance as ACA rates spike
- Kiefer Sutherland arrested after allegedly assaulting a ride-share driver in L.A.
- 2025 Was Another Exceptionally Hot Year
- Freed whale gets stranded again off German coast
- Toyota Motor Europe to roll out smart EV charging through new partnerships
- Carry Nature Inside with These Staggering Plant Decisions
- Instructions to Improve Your Mental Exploration with Cutting edge Measurements
- Independence from the rat race for Recent college grads: Systems and Tips
- 1st human missions to Mars should hunt for signs of life, report says
